220 related articles for article (PubMed ID: 37444515)
1. Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9.
Chan C; Lustig M; Jansen JHM; Garcia Villagrasa L; Raymakers L; Daamen LA; Valerius T; van Tetering G; Leusen JHW
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444515
[TBL] [Abstract][Full Text] [Related]
2. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.
Lustig M; Chan C; Jansen JHM; Bräutigam M; Kölling MA; Gehlert CL; Baumann N; Mester S; Foss S; Andersen JT; Bastian L; Sondermann P; Peipp M; Burger R; Leusen JHW; Valerius T
Front Immunol; 2023; 14():1178817. PubMed ID: 37346044
[TBL] [Abstract][Full Text] [Related]
3. SIGLEC-5/14 Inhibits CD11b/CD18 Integrin Activation and Neutrophil-Mediated Tumor Cell Cytotoxicity.
Bouti P; Blans C; Klein BJAM; Shome D; Nadafi R; Van Houdt M; Schornagel K; Verkuijlen PJJH; Roos V; Reijmers RM; Van Bruggen R; Kuijpers TW; Matlung HL
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38138970
[TBL] [Abstract][Full Text] [Related]
4. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
[TBL] [Abstract][Full Text] [Related]
5. Enhancing IgA-mediated neutrophil cytotoxicity against neuroblastoma by CD47 blockade.
Chan C; Stip M; Nederend M; Jansen M; Passchier E; van den Ham F; Wienke J; van Tetering G; Leusen J
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38782540
[TBL] [Abstract][Full Text] [Related]
6. Siglec-5 is an inhibitory immune checkpoint molecule for human T cells.
Vuchkovska A; Glanville DG; Scurti GM; Nishimura MI; White P; Ulijasz AT; Iwashima M
Immunology; 2022 Jun; 166(2):238-248. PubMed ID: 35290663
[TBL] [Abstract][Full Text] [Related]
7. CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells.
Martínez-Sanz P; Hoogendijk AJ; Verkuijlen PJJH; Schornagel K; van Bruggen R; van den Berg TK; Tytgat GAM; Franke K; Kuijpers TW; Matlung HL
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503071
[TBL] [Abstract][Full Text] [Related]
8. Siglec Signaling in the Tumor Microenvironment.
van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
Front Immunol; 2021; 12():790317. PubMed ID: 34966391
[TBL] [Abstract][Full Text] [Related]
9. Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils.
Behrens LM; van den Berg TK; van Egmond M
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884427
[TBL] [Abstract][Full Text] [Related]
10. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
Bärenwaldt A; Läubli H
Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
[No Abstract] [Full Text] [Related]
11. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity.
Ibarlucea-Benitez I; Weitzenfeld P; Smith P; Ravetch JV
Proc Natl Acad Sci U S A; 2021 Jun; 118(26):. PubMed ID: 34155121
[TBL] [Abstract][Full Text] [Related]
12. Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy: A Novel Anti-Cancer Strategy With IgA Antibodies?
Chan C; Lustig M; Baumann N; Valerius T; van Tetering G; Leusen JHW
Front Immunol; 2022; 13():932155. PubMed ID: 35865547
[TBL] [Abstract][Full Text] [Related]
13. Tumor cell-intrinsic and tumor microenvironmental conditions co-determine signaling by the glycoimmune checkpoint receptor Siglec-7.
van Houtum EJH; Kers-Rebel ED; Looman MW; Hooijberg E; Büll C; Granado D; Cornelissen LAM; Adema GJ
Cell Mol Life Sci; 2023 May; 80(6):169. PubMed ID: 37253806
[TBL] [Abstract][Full Text] [Related]
14. Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.
Daly J; Carlsten M; O'Dwyer M
Front Immunol; 2019; 10():1047. PubMed ID: 31143186
[TBL] [Abstract][Full Text] [Related]
15. Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands.
Boelaars K; van Kooyk Y
Trends Cancer; 2024 Mar; 10(3):230-241. PubMed ID: 38160071
[TBL] [Abstract][Full Text] [Related]
16. Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities.
Haas Q; Markov N; Muerner L; Rubino V; Benjak A; Haubitz M; Baerlocher GM; Ng CKY; Münz C; Riether C; Ochsenbein AF; Simon HU; von Gunten S
Front Immunol; 2022; 13():996746. PubMed ID: 36211376
[TBL] [Abstract][Full Text] [Related]
17. Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment.
van de Wall S; Santegoets KCM; van Houtum EJH; Büll C; Adema GJ
Trends Immunol; 2020 Apr; 41(4):274-285. PubMed ID: 32139317
[TBL] [Abstract][Full Text] [Related]
18. Tools to study and target the Siglec-sialic acid axis in cancer.
Läubli H; Kawanishi K; George Vazhappilly C; Matar R; Merheb M; Sarwar Siddiqui S
FEBS J; 2021 Nov; 288(21):6206-6225. PubMed ID: 33251699
[TBL] [Abstract][Full Text] [Related]
19. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.
Läubli H; Pearce OM; Schwarz F; Siddiqui SS; Deng L; Stanczak MA; Deng L; Verhagen A; Secrest P; Lusk C; Schwartz AG; Varki NM; Bui JD; Varki A
Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14211-6. PubMed ID: 25225409
[TBL] [Abstract][Full Text] [Related]
20. Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab.
Baumann N; Arndt C; Petersen J; Lustig M; Rösner T; Klausz K; Kellner C; Bultmann M; Bastian L; Vogiatzi F; Leusen JHW; Burger R; Schewe DM; Peipp M; Valerius T
Front Immunol; 2022; 13():949140. PubMed ID: 36052078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]